Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Fintel reports that on January 23, 2025, Barclays downgraded their outlook for Galapagos NV - Depositary Receipt () (NasdaqGS:GLPG) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 48 ...

Barclays downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of EUR 22, down from EUR 30. With Galapagos’ ongoing ...

Galapagos NV (NASDAQ:GLPG – Get Free Report) has received an average recommendation of “Reduce” from the eight research firms ...

In trading on Thursday, shares of Galapagos NV (Symbol: GLPG) crossed above their 200 day moving average of $28.06, changing hands as high as $28.22 per share. Galapagos NV shares are currently ...

Galapagos NV (NASDAQ:GLPG) is under modest pressure premarket, down 6% on increased volume on the heels of promising results from Vertex Pharmaceuticals' (NASDAQ:VRTX) triple... BySeeking Alpha ...

In trading on Monday, shares of Galapagos NV (Symbol: GLPG) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $24.145 per share. By comparison ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...